Education
About Us
Working with TipRanks
Follow Us
Catheter Precision (VTAK)
XASE:VTAK
VTAK Stock Chart & Stats
$1.81
-$0.02(-4.26%)
At close: 4:00 PM EST
$1.81
-$0.02(-4.26%)
Day’s Range― - ―
52-Week Range$1.14 - $15.68
Previous CloseN/A
Volume115.56K
Average Volume (3M)309.34K
Market Cap
$2.40M
Enterprise Value$4.17M
Total Cash (Recent Filing)$1.07M
Total Debt (Recent Filing)$3.48M
Price to Earnings (P/E)―
Beta1.71
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,668,375
10 Day Avg. Volume759,143
30 Day Avg. Volume309,336
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.38
Price to Sales (P/S)66.59
P/FCF Ratio-3.00
Enterprise Value/Market Cap1.74
Enterprise Value/Revenue5.72
Enterprise Value/Gross Profit28.21
Enterprise Value/Ebitda-0.31
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent TTM revenue growth (~+21.7% to $0.73M) signals early commercial traction for its cardiac mapping platform. Sustained top-line expansion over the next 2–6 months can help absorb fixed R&D and sales costs, improve unit economics, and support progress toward scalable revenue and eventual breakeven.
FDA-cleared ProductAn FDA-cleared cardiac mapping system is a durable competitive asset: it reduces regulatory adoption barriers, supports hospital purchasing and clinical trust, and enables incremental software and hardware iterations that reinforce clinical stickiness and long-term market positioning.
Recurring Revenue StreamsConsumables, catheters and service/maintenance contracts create recurring revenue and customer lock-in. Predictable repeat sales to installed customers raise lifetime value, smooth revenue volatility, and offer a scalable foundation for margin improvement as the installed base grows over several quarters.
Bears Say
High Cash BurnSubstantial TTM cash burn (~-$9.6M operating and free cash flow) is a structural vulnerability given modest revenues. Persistent negative cash flow forces dependence on external financing or insider support and constrains investments in commercialization or R&D unless cash consumption meaningfully falls.
Weak ProfitabilityLow gross margin (~20%) combined with extremely negative net margins (~-2,381%) indicate the business yields little profit per sale while fixed operating costs are high. Structural margin weakness means scaling revenue alone may not restore profitability without material cost reduction or higher-margin product adoption.
Reliance On Insider FinancingAmendments extending CEO/affiliate promissory notes through 2028–2029 underscore ongoing dependence on insider financing and concentrated governance influence. This signals constrained external financing access, elevating liquidity, governance and dilution risk that can limit strategic flexibility over the medium term.
Catheter Precision News
VTAK FAQ
What was Catheter Precision’s price range in the past 12 months?
Catheter Precision lowest stock price was $1.14 and its highest was $15.68 in the past 12 months.
What is Catheter Precision’s market cap?
Catheter Precision’s market cap is $2.40M.
When is Catheter Precision’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Catheter Precision’s earnings last quarter?
Currently, no data Available
Is Catheter Precision overvalued?
According to Wall Street analysts Catheter Precision’s price is currently Overvalued.
Does Catheter Precision pay dividends?
Catheter Precision does not currently pay dividends.
What is Catheter Precision’s EPS estimate?
Catheter Precision’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Catheter Precision have?
Catheter Precision has 1,668,375 shares outstanding.
What happened to Catheter Precision’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Catheter Precision?
Currently, no hedge funds are holding shares in VTAK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Catheter Precision
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.
Technical Analysis
Ownership Overview
0.84%
Insiders
0.20% Mutual Funds
― Other Institutional Investors
98.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---